| Execution period | Not Applicable |
|---|
NSE filing, NSE: SENORES. Summary written from the filing by ALFA Finder's alert engine.
Senores Pharmaceuticals Ltd: key numbers
- Share price
- ₹1,294.80
- Market cap
- ₹5,963 Cr
- Revenue (annual)
- ₹632.6 Cr
- Net profit (annual)
- ₹115.4 Cr
- P/E (TTM)
- 47.2×Sector 46.1×
- Promoter holding
- 45.82%+0.00% QoQ
- FII holding
- 6.01%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Senores Pharmaceuticals Ltd
All →Senores Pharmaceuticals Board Meeting Date
Senores Pharmaceuticals has scheduled a board meeting for October 29, 2026, to approve its unaudited financial results for the quarter and half-year ended September 30, 2026.
Senores Pharmaceuticals Annual General Meeting
Senores Pharmaceuticals Limited has issued a Postal Ballot Notice seeking shareholder approval for the re-appointment of its Managing Director and Whole Time Director. The e-voting period concludes on November 17, 2026.
Senores Pharmaceuticals Management Change
Senores Pharmaceuticals re-appointed Swapnil Shah as MD and Chetan Shah as WTD for three-year terms. Both appointments are subject to shareholder approval via postal ballot.
Senores Pharmaceuticals Other Announcement
Senores Pharmaceuticals submitted its Reconciliation of Share Capital Audit Report for the quarter ended September 30, 2026, as required by SEBI regulation 76.
Senores Pharmaceuticals Annual General Meeting
Senores Pharmaceuticals held its 9th Annual General Meeting on September 25, 2026. Shareholders approved financial statements, director appointments, and the new Employee Stock Option Scheme 2026.
Senores Pharmaceuticals Price Movement Clarification
Senores Pharmaceuticals informed exchanges there is no undisclosed or price-sensitive information behind the volume spike. The company affirmed compliance with SEBI LODR disclosure obligations.
Other merger & restructuring announcements
All →Raghav Productivity Enhancers Merger & Restructuring
RPEL acquired 80% of JV entity RPEL TRLK Silicatech Pvt Ltd for Rs. 80,000. The Odisha-based entity will manufacture silica ramming mass and refractories.
Mohite Industries Merger & Restructuring
Mohite Industries seeks postal ballot approval to sell its spinning unit land and plant to unidentified buyers, and to shift registered office. E-voting closes 29 November 2026.
Reliance Industries Merger & Restructuring
Reliance disclosed that UK registrar published a gazette notice for voluntary strike-off of step-down subsidiary Hamleys (Franchising) Limited. HFL contributed 0.0048% of consolidated turnover, so impact is negligible.
Quint Digital Merger & Restructuring
Quint Digital's board approved a Rule 10b5-1 trading plan and the incorporation of a wholly owned overseas subsidiary. No investment amount was disclosed.
Hexaware Technologies Merger & Restructuring
Hexaware Technologies approved a slump sale of its step-down subsidiary Tech SMC Square India to Tech SMC Squared (GCC) India, a related-party deal. Consideration is cash, yet to be set by a registered valuer.
- Execution
- Expected completion by 30 June 2027; agreement date stated as 1 December 2026
Emkay Global Financial Services Merger & Restructuring Worth ₹2.75 Cr
Emkay Global agreed to sell its Wealth Management Business to a step-down subsidiary, Emkay Wealth Advisory, for Rs. 2.75 Crore cash. Completion is expected by 26 January 2027.
- Value
- ₹2.75 Cr
- Execution
- Completion expected by 26 January 2027